Treatment of schizophrenia: Preventing the progression of disease

Psychiatric Clinics of North America

Volumn 26, Issue 2, 2003, Pages 367-379

  Csernansky, John G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE DECANOATE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEART DISEASE; HOSPITAL CHARGE; HUMAN; MAINTENANCE THERAPY; METABOLIC DISORDER; PARKINSONISM; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0037910073     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00113-2     Document Type: Review

References (70)

1. Hollister LE, Csernansky JG. Clinical pharmacology of psychotherapeutic drugs. New York: Churchill Livingstone; 1990. p. 97-126.
2. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32(3):229-313.
3. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976;2:19-76.
4. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975;2:657.
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
6. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine, D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
9. Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol Bull 1993;112:285-92.
10. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-13.
11. 11C] raclopride. Neuropsychopharmacology 2002;27:248-59.
12. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings and mechanisms. Arch Gen Psychiatry 1995;52:341-51.
13. Tollefson GE, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
14. Arvanitis L, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
15. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
16. Liddle PF. The symptoms of chronic schizophrenia: A reexamination of the positivenegative dichotomy. Br J Psychiatry 1987;151:145-51.
17. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bull 2002;28:5-16.
18. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia. a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-8.
19. Saykin A, Shtasel D, Gur RE, Kester D, Mozley L, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-31.
20. Green MF. What are the consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
21. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999;46:899-907.
22. Doering S, Muller E, Kopcke W, Pietzcker A, Gaebel W, Linden M, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Bull 1998;24:87-98.
23. McCreadie RG. Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacology 1996;6:S2-5.
24. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, Seroquel) and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
25. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
26. Keck PE, Reeves KR, Harringan EP. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001;21:27-35.
27. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
28. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bull 2002;28:17-29.
29. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Berasley C Jr. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
30. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
31. Carson WH, McQuade RD, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr Res 2001;49:221.
32. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
33. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28.
34. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
35. Allison DB, Mentore JL, Heo M, Chandler LP, Cappellieri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
36. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
37. Daniel DG, Copeland LF. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opinion on Investigational Drugs 2000;9:819-28.
38. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153-7.
39. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
40. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22.
41. Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985;11:18-21.
42. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, editor. Psychopharmacology, the third generation of progress: the emergence of molecular biology and biological psychiatry. New York: Raven Press; 1987. p. 1103-9.
43. Hogarty GE, McEvoy JP, Munetz M, DuBarry AL, Bartone P, Cather R, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988;45:797-805.
44. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518-21.
45. Kane JM, Davis JM, Schooler NR, Marder SR, Brauzer B, Casey DE. A one-year comparison of four dosages of haloperidol decanoate. Schizophr Res 1993;9:239-40.
46. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
47. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
48. Purdon SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci 2000;25:108-16.
49. Di Lorenzo R, Tondelli G, Genedani S. Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients. International Journal Neuropsychopharmacology 2001;4:135-7.
50. Lindstrom E, Eriksson B, Hellgren A, von Knnorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-12.
51. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
52. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-7.
53. Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15:245-55.
54. Eerdekens M, Fleischhacker WW, Xie Y, Beauclair L, Sauret H, Chrzanowski W, et al. Long-term safety of long-acting risperidone microspheres. Presented at the World Psychiatric Association Annual Meeting. Yokohama (Japan), August 24-29, 2002.
55. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001;62(Suppl 23):39-44.
56. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
57. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001;50:148-9.
58. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992;149:844-5.
59. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(Suppl 23):5-12.
60. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl 21):25-30.
61. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998;59(Suppl 19):9-17.
62. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001;58:158-64.
63. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8.
64. Knapp M. Schizophrenia costs and treatment cost effectiveness. Acta Psychiatrica Scandinavica 2000;102(Suppl 407):15-8.
65. Rosenheck R, Cramer JW, Thomas J, Henderson W, Frisman L. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-15.
66. Jonsson D, Walinder J. Cost effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatrica Scandinavica 1995;92:199-201.
67. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990;41:882-5.
68. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 1998;55(Suppl 4):S17-9.
69. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-8.
70. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9.